Spots Global Cancer Trial Database for mirdametinib
Every month we try and update this database with for mirdametinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | NCT04923126 | Low-Grade Gliom... Recurrent Low-G... Progressive Low... | Mirdametinib | 2 Years - 24 Years | St. Jude Children's Research Hospital | |
| Mirdametinib + BGB-3245 in Advanced Solid Tumors | NCT05580770 | Advanced Solid ... | Mirdametinib BGB-3245 | 18 Years - | SpringWorks Therapeutics, Inc. | |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | NCT05054374 | Breast Cancer Breast Cancer S... HER2-negative B... Solid Carcinoma MEK1 Gene Mutat... MEK2 Gene Mutat... Metastatic Brea... | Mirdametinib Fulvestrant | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | NCT03905148 | Solid Tumor, Ad... | Lifirafenib mirdametinib | 18 Years - | BeiGene | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). | NCT06159166 | NF1 Cutaneous Neuro... Monotherapy | Mirdametinib | 18 Years - | Johns Hopkins University | |
| Mirdametinib + BGB-3245 in Advanced Solid Tumors | NCT05580770 | Advanced Solid ... | Mirdametinib BGB-3245 | 18 Years - | SpringWorks Therapeutics, Inc. | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
